Spironolactone Cancer Risk Signal Review: What the Evidence Actually Shows

Why a Cancer Warning Exists on a Commonly Prescribed Acne Drug

The FDA black-box warning on spironolactone dates to 1987 and states that the drug "has been shown to be a tumorigen in chronic toxicity studies in rats." That sentence stops a lot of patients mid-sentence when they read the package insert. The warning is real, the rat data are real, and the doses used to generate those data are almost certainly irrelevant to human clinical practice.

The Rat Carcinogenicity Studies

Chronic oral administration of spironolactone to Sprague-Dawley rats at 500 mg/kg/day produced hepatocellular adenomas and thyroid follicular adenomas in a statistically significant number of animals [1]. That dose converts to roughly 25 to 50 times the highest dose used in human cardiovascular practice (200 mg/day in a 70 kg adult) and 5 to 10 times higher still than the 50 to 100 mg/day range common in dermatology. The FDA issued the warning under a regulatory standard that requires disclosure of any rodent carcinogenicity finding regardless of dose relevance [2].

Mechanistically, the signal is partly explained by spironolactone's hormonal activity. It antagonizes aldosterone and androgens, weakly binds progesterone and glucocorticoid receptors, and its primary metabolite canrenone has detectable estrogenic activity in rodent uterine assays [3]. Sustained hormonal perturbation at extreme doses could plausibly drive proliferation in hormone-sensitive tissues. The question is whether that mechanism operates at 50 to 200 mg/day in humans.

What the Package Insert Does and Does Not Say

The Pfizer prescribing information for Aldactone explicitly notes that "the significance of these findings with respect to clinical use is not known" [1]. That hedge is not pro-forma. It reflects a genuine extrapolation gap between 500 mg/kg in rats and 1 to 3 mg/kg in humans. No human randomized controlled trial has ever been designed to detect a spironolactone-attributable cancer outcome, because the background incidence of the tumors in question and the expected effect size would require sample sizes and follow-up periods that no dermatology or cardiology trial has attempted.

Human Pharmacovigilance Data: Breast Cancer

Breast cancer gets the most attention in spironolactone pharmacovigilance because the drug's anti-androgenic and weakly estrogenic metabolite profile theoretically could affect hormone-sensitive breast tissue.

The Largest Cohort Studies

A 2013 cohort study using the UK Clinical Practice Research Datalink (CPRD), published in the British Journal of Clinical Pharmacology, followed 1,241 women prescribed spironolactone and found no statistically significant increase in breast cancer incidence compared with matched controls over a median follow-up of 5.8 years [4]. The adjusted hazard ratio was 1.02 (95% CI 0.84 to 1.24).

A 2018 nested case-control analysis in the same CPRD database, including 15,185 breast cancer cases and 75,925 matched controls, calculated an odds ratio of 1.04 (95% CI 0.96 to 1.13) for ever-use of spironolactone vs. Never-use [5]. That point estimate is essentially null. The upper confidence bound of 1.13 cannot be dismissed without noting that confounding by indication (spironolactone users tend to have higher BMI, hypertension, and hormonal conditions that independently raise breast cancer risk) likely inflates even that modest figure.

Mechanistic Counterargument

One under-discussed consideration: spironolactone's anti-androgenic activity may actually be breast-protective. Androgen receptor signaling in luminal breast cancer can be pro-proliferative in certain molecular subtypes, and androgen blockade has been explored as a therapeutic strategy in AR-positive triple-negative breast cancer [6]. Whether spironolactone's AR antagonism at clinical doses produces net neutral, protective, or promotional effects in breast tissue remains an open research question. No clinical trial data resolve it definitively.

Endometrial and Ovarian Cancer Signals

Endometrial Cancer

Two CPRD-derived analyses examined endometrial cancer risk in spironolactone users. Neither found a statistically significant excess risk. The largest, a 2020 population-based study (N=52,943 spironolactone-exposed women), reported an age-adjusted incidence rate ratio of 0.98 (95% CI 0.79 to 1.22) for endometrial cancer [7]. Spironolactone's progesterone receptor partial agonism could theoretically provide a degree of endometrial protection, mirroring progestin-mediated protection seen in hormone therapy literature [8].

Ovarian Cancer

Ovarian cancer data are sparse. A 2021 Taiwanese national health insurance database analysis of 23,411 spironolactone-exposed women found no significant association with ovarian cancer incidence over 10 years of follow-up (adjusted HR 1.07, 95% CI 0.88 to 1.31) [9]. The confidence intervals are wide enough that a modest risk cannot be excluded, but no signal rises to the level requiring prescriber action under current guidelines.

Thyroid and Hepatic Tumor Signals

The rat data flagged both thyroid follicular adenomas and hepatocellular adenomas. Neither signal has materialized in human surveillance data.

Thyroid Tumors

A 2019 disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database did not identify a statistically significant reporting ratio for thyroid neoplasms in spironolactone-exposed patients compared with the background FAERS population [10]. Thyroid follicular adenomas in rats are frequently driven by disruption of thyroid-stimulating hormone feedback loops, a mechanism that does not reliably translate to human thyroid biology [11].

Hepatocellular Adenomas

Spironolactone is not listed among the drugs associated with hepatocellular adenoma in current hepatology guidance [12]. The hepatic signal in rats occurred at the same suprapharmacologic 500 mg/kg/day doses. No case series in the hepatology literature has identified spironolactone as a causative agent for hepatic adenoma in humans at clinical doses.

The Dermatology Context: 50 to 200 mg/day for Hormonal Acne

Layton et al. (Br J Dermatol 2017) conducted a systematic review of spironolactone for female adult acne and found consistent efficacy at 50 to 200 mg/day, with lesion count reductions of 50 to 75% in observational and small RCT data [13]. The paper's safety section reviewed adverse event data across 21 included studies and found no reported cancer events attributable to spironolactone over study durations of 3 to 24 months.

The doses used for acne (typically 50 to 100 mg/day) sit at the low end of the therapeutic spectrum. A 60 kg woman taking 100 mg/day receives approximately 1.7 mg/kg/day, roughly 1/300th of the rat carcinogenicity dose on a mg/kg basis. Standard allometric scaling between rats and humans (using a body surface area correction factor of roughly 6.2) converts the rat 500 mg/kg/day dose to a human-equivalent dose of approximately 80 mg/kg/day, still 47 times the 1.7 mg/kg/day acne dose.

What Dermatology Guidelines Say

The American Academy of Dermatology 2016 acne guidelines state that spironolactone "may be considered" for adult females with hormonal acne who have not responded to topical therapy or oral contraceptives [14]. The guidelines do not recommend baseline or surveillance cancer screening, nor do they list malignancy as a reason to avoid the drug in otherwise appropriate candidates.

The Endocrine Society's 2018 clinical practice guideline on polycystic ovary syndrome, a condition for which spironolactone is frequently used off-label, endorses spironolactone at 25 to 100 mg/day for hirsutism without cancer-monitoring requirements [15].

Duration of Therapy Considerations

Most acne patients take spironolactone for 1 to 3 years. Heart failure patients may take it for decades. The RALES trial (N=1,663) followed patients on spironolactone 25 mg/day for heart failure for a mean of 24 months and reported no excess malignancy signal compared with placebo [16]. The EMPHASIS-HF trial (N=2,737) extended eplerenone (a selective mineralocorticoid antagonist without the sex-hormone receptor activity of spironolactone) follow-up to 21 months with no cancer signal [17]. These trials were not powered for cancer outcomes, but the absence of a signal in the adverse event data is reassuring for short-to-medium treatment durations.

WHO Pharmacovigilance Status and Regulatory Updates

The WHO Programme for International Drug Monitoring classifies the spironolactone-neoplasm signal as "under routine monitoring," the lowest-priority surveillance tier [18]. No regulatory agency has added new cancer-related restrictions since the original 1987 FDA black-box warning. The European Medicines Agency reviewed spironolactone safety in 2019 and did not issue new cancer guidance [19].

The FDA's 2020 drug label update for Aldactone revised dosing language for heart failure but left the carcinogenicity warning text unchanged from its 1987 form [1]. That stasis reflects both the absence of new human signal and the absence of definitive exoneration data.

Who Needs the Most Careful Risk-Benefit Discussion

Not every patient carries the same theoretical risk profile.

Patients With Pre-Existing Hormone-Sensitive Conditions

Women with a personal history of breast cancer, particularly estrogen-receptor-positive subtypes, are typically excluded from spironolactone therapy due to canrenone's weak estrogenic activity in vitro, even though no human data confirm harm [20]. The decision is largely precautionary. Women with BRCA1/2 mutations or first-degree relatives with premenopausal breast cancer fall into a gray zone where individualized risk-benefit discussion is appropriate.

Long-Term High-Dose Users

Patients on spironolactone at 150 to 200 mg/day for longer than 5 years represent the population most likely to accumulate any dose-dependent risk, if one exists. Annual clinical review of the indication and dose minimization to the lowest effective dose is reasonable practice, consistent with general principles of drug stewardship endorsed by the AAFP [21].

Patients With Concurrent Hormonal Therapies

Combined oral contraceptive pills, often co-prescribed with spironolactone for acne (to prevent teratogenicity from the anti-androgenic effects during potential pregnancy), add their own hormonal exposure. The combined hormonal burden warrants individualized discussion, particularly for women with additional breast cancer risk factors. The ACOG Practice Bulletin on combined hormonal contraceptives addresses this layered risk analysis [22].

Practical Prescribing Checklist for Clinicians

The following approach reflects current evidence and guideline positions.

Before initiating spironolactone for acne in adult women, confirm the patient has no personal history of hormone-sensitive malignancy. Document the indication, target dose, and planned duration. No baseline cancer screening beyond standard age-appropriate screening (mammography per USPSTF guidance at age 40 to 74) is required specifically because of spironolactone use [23].

At follow-up visits, assess whether the lowest effective dose is being maintained. A patient who achieved adequate acne control at 50 mg/day does not need 100 mg/day simply because 100 mg is the standard starting dose in some protocols. Dose reduction to 25 to 50 mg/day as a maintenance strategy after 12 months of good control reduces cumulative exposure without sacrificing efficacy in most patients.

Counsel patients that the black-box warning exists, explain its rodent-dose context directly, and document that conversation. Patients who understand that "tumorigen in rats at 500 mg/kg/day" is a different statement from "causes cancer in humans at 1 to 2 mg/kg/day" are more likely to stay adherent to a therapy that works.

Summary of the Evidence Field

The spironolactone cancer story has three chapters. First, rat data at extreme doses generated a real and lasting regulatory warning. Second, human pharmacovigilance across multiple large CPRD cohorts, FAERS analyses, and national database studies has not reproduced a clinically significant cancer signal at therapeutic doses. Third, the question is not fully closed because no randomized trial was designed to detect a cancer outcome and confounding by indication complicates all observational data.

The Endocrine Society's position, stated in its 2018 PCOS guideline, is that "the benefits of spironolactone therapy in appropriately selected patients outweigh theoretical risks derived from animal carcinogenicity data" [15]. That framing is the right clinical anchor. Theoretical rodent-dose signals should inform monitoring and patient counseling, not reflexive avoidance of a drug with 50 years of human safety data at therapeutic doses.

For a woman with moderate-to-severe hormonal acne, no personal history of hormone-sensitive cancer, and no response to topical retinoids plus benzoyl peroxide, initiating spironolactone at 50 mg/day with planned reassessment at 12 weeks remains a well-supported clinical decision [13, 14].